These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 11042519)

  • 1. Serum CD44 levels preceding the diagnosis of non-Hodgkin's lymphoma.
    Mäenpää H; Ristamäki R; Virtamo J; Franssila K; Albanes D; Joensuu H
    Leuk Lymphoma; 2000 May; 37(5-6):585-92. PubMed ID: 11042519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated serum CD44 level is associated with unfavorable outcome in non-Hodgkin's lymphoma.
    Ristamäki R; Joensuu H; Lappalainen K; Teerenhovi L; Jalkanen S
    Blood; 1997 Nov; 90(10):4039-45. PubMed ID: 9354673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum CD44 in non-Hodgkin's lymphoma.
    Ristamäki R; Joensuu H; Jalkanen S
    Leuk Lymphoma; 1999 May; 33(5-6):433-40. PubMed ID: 10342571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of circulating CD44 in non-Hodgkin's lymphoma.
    Ristamäki R; Joensuu H; Hagberg H; Kalkner KM; Jalkanen S
    Int J Cancer; 1998 Jun; 79(3):221-5. PubMed ID: 9645341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of soluble CD44 in patients with breast and colorectal carcinomas and non-Hodgkin's lymphoma.
    Lockhart MS; Waldner C; Mongini C; Gravisaco MJ; Casanova S; Alvarez E; Hajos S
    Oncol Rep; 1999; 6(5):1129-33. PubMed ID: 10425314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High serum soluble CD44 is correlated with a poor outcome of aggressive non-Hodgkin's lymphoma.
    Niitsu N; Iijima K
    Leuk Res; 2002 Mar; 26(3):241-8. PubMed ID: 11792412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum osteopontin and CD44 levels in lymphoreticular malignancies in children.
    Elli M; Dagdemir A; Bozkurt C; Pinarli FG; Duzgun A; Ozmen ZC; Ertem U; Acar S
    Bratisl Lek Listy; 2012; 113(9):534-8. PubMed ID: 22979908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated serum levels of soluble CD44 variant 6 are correlated with shorter survival in aggressive non-Hodgkin's lymphoma.
    Sasaki K; Niitsu N
    Eur J Haematol; 2000 Sep; 65(3):195-202. PubMed ID: 11007056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum levels and differential expression of CD44 in childhood leukemia and malignant lymphoma: correlation with prognostic criteria and survival.
    Taçyildiz N; Cavdar AO; Yavuz G; Gözdaşoglu S; Unal E; Ertem U; Duru F; Ikinciogullari A; Babacan E; Kuzu I; Cin S
    Pediatr Int; 2001 Aug; 43(4):354-60. PubMed ID: 11472578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms.
    Kurzrock R; Redman J; Cabanillas F; Jones D; Rothberg J; Talpaz M
    Cancer Res; 1993 May; 53(9):2118-22. PubMed ID: 8481913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomas.
    Shah N; Cabanillas F; McIntyre B; Feng L; McLaughlin P; Rodriguez MA; Romaguera J; Younes A; Hagemeister FB; Kwak L; Fayad L
    Leuk Lymphoma; 2012 Jan; 53(1):50-6. PubMed ID: 21895545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated levels of soluble CD44 precede the development of AIDS-associated non-Hodgkin's B-cell lymphoma.
    Breen EC; Epeldegui M; Boscardin WJ; Widney DP; Detels R; Martínez-Maza O
    AIDS; 2005 Oct; 19(15):1711-2. PubMed ID: 16184051
    [No Abstract]   [Full Text] [Related]  

  • 13. Serum hyaluronan is increased in malignant lymphoma.
    Hasselbalch H; Hovgaard D; Nissen N; Junker P
    Am J Hematol; 1995 Dec; 50(4):231-3. PubMed ID: 7485095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of the serum IL-2R level and Ga-67 scan findings in making a differential diagnosis between sarcoidosis and non-Hodgkin's lymphoma.
    Kita T; Watanabe S; Yano F; Hayashi K; Yamamoto M; Iwasaki Y; Kosuda S
    Ann Nucl Med; 2007 Nov; 21(9):499-503. PubMed ID: 18030581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of serum CD44 measurement in malignant lymphoma.
    Fukuda Y
    Kurume Med J; 2001; 48(1):65-9. PubMed ID: 11402623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical implications of serum levels of soluble CD23 and tumor necrosis factor alpha in low-grade non-Hodgkin's lymphoma.
    Zinzani PL; Baccini C; Zaccaria A; Visani G; Buzzi M; Morelli A; Molinari AL; Salvucci M; Bendandi M; Rubboli D; Gherlinzoni F; Zanchini R; Tura S
    Eur J Haematol; 1996 Nov; 57(5):335-40. PubMed ID: 9003473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble CD44 splice variants and pelvic lymph node metastasis in ovarian cancer patients.
    Stickeler E; Vogl FD; Denkinger T; Mobus VJ; Kreienberg R; Runnebaum IB
    Int J Mol Med; 2000 Nov; 6(5):595-601. PubMed ID: 11029531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients.
    Warzocha K; Salles G; Bienvenu J; Bastion Y; Dumontet C; Renard N; Neidhardt-Berard EM; Coiffier B
    J Clin Oncol; 1997 Feb; 15(2):499-508. PubMed ID: 9053471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of treatment on the prognostic value of S-phase fraction in non-Hodgkin's lymphoma.
    Joensuu H; Ristamäki R; Söderström KO; Jalkanen S
    J Clin Oncol; 1994 Oct; 12(10):2167-75. PubMed ID: 7931487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum CA 125 as a prognostic factor in non-Hodgkin's lymphoma.
    Bairey O; Blickstein D; Stark P; Prokocimer M; Nativ HM; Kirgner I; Shaklai M
    Leuk Lymphoma; 2003 Oct; 44(10):1733-8. PubMed ID: 14692526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.